Biotech entity
pharma is the sole category represented across all 1 tracked stories. Antonin Scalia is most often covered alongside Babbitt v. Sweet Home Chapter of Communities for a Great Oregon, which appears in 1 of these 1 story. Each carries 2 original sources on average.
Last mentioned: Jul 15, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Antonin Scalia is most often covered alongside Babbitt v. Sweet Home Chapter of Communities for a Great Oregon, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Antonin Scalia, all published on July 15, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Antonin Scalia. Shared-story counts are live from our verified record — not editorial picks.
The rescission of the ESA's 'harm' definition removes a major regulatory hurdle for biotech and pharma facility construction near sensitive habitats. Starting September 12, 2026, indirect habitat impacts will no longer trigger 'take' liability, potentially accelerating project timelines and reducing permitting costs for life-science companies.
Antonin Scalia is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
